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Abstract
Purpose Radiopharmaceutical extravasation can potentially
lead to severe soft tissue damage, but little is known about
incidence, medical consequences, possible interventions, and
effectiveness of these. The aims of this study are to estimate
the incidence of extravasation of diagnostic and therapeutic
radiopharmaceuticals, to evaluate medical consequences, and
to evaluate medical treatment applied subsequently to those
incidents.
Methods A sensitive and elaborate literature search was per-
formed in Embase and PubMed using the keywords Bmisad-
ministration^, Bextravasation^, Bparavascular infiltration^,
combined with Btracer^, Bradionuclide^, Bradiopharmaceuti-
cal^, and a list of keywords referring to clinically used tracers
(i.e. BTechnetium-99m^, BYttrium-90^). Reported data on ra-
diopharmaceutical extravasation and applied interventions
was extracted and summarised.
Results Thirty-seven publications reported 3016 cases of di-
agnostic radiopharmaceutical extravasation, of which three
cases reported symptoms after extravasation. Eight publica-
tions reported 10 cases of therapeutic tracer extravasation.
The most severe symptom was ulceration. Thirty-four differ-
ent intervention and prevention strategies were performed or
proposed in literature.
Conclusions Extravasation of diagnostic radiopharmaceuti-
cals is common. 99mTc, 123I, 18F, and 68Ga labelled tracers
do not require specific intervention. Extravasation of thera-
peutic radiopharmaceuticals can give severe soft tissue le-
sions. Although not evidence based, surgical intervention
should be considered. Furthermore, dispersive intervention,
dosimetry and follow up is advised. Pharmaceutical interven-
tion has no place yet in the immediate care of radiopharma-
ceutical extravasation.
Keywords Extravasation . Dose infiltration .
Radiopharmaceuticals . Radiation ulcer
Introduction
High doses of radiation exposure can potentially cause severe
tissue damage, such as skin desquamation and necrosis.
Extravasation of radionuclides used in nuclear medicine prac-
tice results in localized tissue retention of the radiopharmaceu-
tical and subsequently in an unintended extended local radia-
tion exposure. Because of the character of the radiation, ex-
travasation of therapeutic radiopharmaceuticals has the
highest tendency to result in tissue damage, although some
cases of tissue damage following the extravasation of diag-
nostic radiopharmaceuticals have been reported [1].
Knowledge of possible consequences and interventions to
prevent tissue damage are vital for an adequate risk-adapted
management after extravasation of radiopharmaceuticals. The
EANM procedure guideline for 90Y-radiolabeled ibritumomab
tiuxetan (Zevalin®) is the only guideline that gives limited
practical advice in case of extravasation, advising local hyper-
thermia, elevation of the extremity and gentle massage [2]. The
SNMMI procedure standard for palliative treatment for painful
bone metastases advises local heat to promote reabsorption [3].
Other EANM and SNMMI guidelines covering radionuclide
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therapy do not give any practical information in case of extrav-
asation, regardless of the potential complications [4–7].
To our knowledge, no previous study or literature review
has been performed to summarize the effects of the extravasa-
tion of commonly applied diagnostic or therapeutic radiophar-
maceuticals. Knowledge of the incidence of extravasation, the
severity of these effects, and about the effectivity of interven-
tions is necessary for adequate clinical response in case of
extravasation, as well as in development of guidelines covering
radiopharmaceutical extravasation. The purpose of this study
was, therefore, to review systematically previously published
data on the incidence and clinical outcome of radioactive ex-
travasations and to summarize the reported incidences of events
of most of the clinically used radiopharmaceuticals, the applied
interventions, as well as the reported clinical outcomes.
Materials and methods
Search strategy
A computer-aided search of the PubMed/MEDLINE and
Embase databases was conducted to find relevant published
articles on extravasation of radiopharmaceuticals. No start
date limit was used. No language limitation was applied in
the initial search strategy. The search string was composed
of several synonymous keywords for extravasation combined
as a group using the BAND^ operator with a combination of
the keywords Bradiopharmaceutical^ and an extensive list of
clinically used isotopes in five different notations (i.e. BI-131^,
BI131^, B131I^, BIodine 131^, B131 iodine^). In PubMed, all
keywords were combined with a MESH equivalent when
available, as well as an equivalent with the BPharmaceutical
action^ tag. The used search strings are shown in Table 1. The
search was updated until November 2016.
Studies reporting radiopharmaceutical extravasation in
humans were eligible for inclusion. Only studies written in
the languages mastered by the authors were included:
English, Spanish, French, Italian, German, Hungarian,
Romanian, or Dutch. No other limits were imposed. Animal
studies were excluded.
Two reviewers (J.P. and S.V.) independently reviewed
titles and abstracts to find articles reporting cases of ex-
travasation, or to find literature otherwise relevant to the
subject. In case of disagreement on relevance, the full text
was retrieved. To expand our search, bibliographies of
articles that finally remained after the selection process
were screened for potentially relevant references.
Subsequently, the corresponding full text articles were re-
trieved for further reading and selection.
Data extraction
The following data were extracted whenever available from
eligible studies: first author, journal and year of publication,
population studied, number of reported extravasations, radio-
pharmaceutical, injection place, estimated administered vol-
ume, estimated extravasated activity and tissue dose, descrip-
tion of tissue damage and delay since injection, duration of
follow-up, and applied medical interventions.
Data analysis
Reported incidents were categorized and pooled according to
radiopharmaceutical that was administered. Ratios were cal-
culated between the pooled reported incidence of extravasa-
tion versus the number of reported incidences of adverse soft
tissue effects. Cases were grouped and displayed in tables
sorted by radiopharmaceutical separately for diagnostic and
therapeutic radiopharmaceuticals. Furthermore, literature ref-
erences that described interventions were organised in three
categories: 1) advised by reference, 2) applied in case report,
and 3) discouraged by reference.
Table 1 Search strings applied in PubMed/MEDLINE and Embase with search results specified to search engine and search strings
No. Search stringsa Pubmed/MEDLINE Embase
1 BExtravasation of Diagnostic and Therapeutic Materials^ [Mesh] OR BExtravasation of Diagnostic
and Therapeutic Materials^ OR Bextravasation^ OR Binfiltration^ OR Bmisadministration^
110.807 171.853
2 BI-123^ OR BI-124^ OR BI-125^ OR BI-131^ OR BTc-99m^ OR BF18^ OR BGa-68^ OR BIn-111^
OR BTl-201^ OR BRb-82^ OR BN-13^ OR BO-15^ OR BC-11^ OR BEr-169^ OR BRe-186^
OR BSr89^ OR BSm-153^ OR BY-90^ OR BRa-223^ OR BP-32^ OR Lu177
213.922 361.049
3 BRadiopharmaceuticals^[Mesh] OR BRadiopharmaceuticals^ OR BRadioisotopes^[Mesh] OR
BRadioisotopes^
301.588 15.949
4 1 AND (2 OR 3) 2.153 3.493
Search strategy with number of yielded results in PubMed/MEDLINE and Embase.
The BMesh^ tag was omitted for the Embase search strings
a In the actual search strings used, all radionuclides were spelled using five different conventions, i.e. the keyword BI-123^ was accompanied by BI123^,
B123I^, BIodine 123^, and B123 Iodine^, grouped together with the BOR^ operand
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Results
The searches performed using Pubmed and Embase resulted
in 2153 and 3493 publications respectively (Table 1). Of
these, 1123 search results were found using both search en-
gines yielding a total of 4523 abstracts after subtraction.
Rejected abstracts described irrelevant animal studies
(1012), reported extravasation of other agents than radionu-
clides (198), mentioned infiltration of other nature than infil-
tration of radiopharmaceuticals (2424), described lymph
drainage studies or other nuclear medicine studies in which
extravasation is a pathological finding, i.e. urinary extravasa-
tion in 99mTc-mercaptoacetyltriglycine (MAG3) (196), or
publications about radionuclide use for other purposes than
nuclear medicine studies (603), such as radioimmunoassays.
The full text was retrieved for the remaining 81 publications.
The references of relevant publications were screened, of
which the full text was retrieved. In total, 108 full text articles
or conference abstracts were retrieved for further evaluation.
Radiopharmaceutical extravasation was reported in 44 publi-
cations, of which 37 about diagnostic and eight about thera-
peutic radiopharmaceuticals. Another 10 publications
contained information on extravasation based on expert opin-
ion or cited work.
Cases of diagnostic extravasation are summarised in Table 2.
In total, 37 publications reported 3016 cases of radiopharma-
ceutical extravasation. For three cases symptoms and follow up
was reported (0,1%) [42–44].When grouped together, a total of
3003 cases described extravasation without reported symptoms
after extravasation of 18F-fluorodeoxyglucose (FDG) (332)
and 99mTc-labelled tracers (2671) [8–41]. Radiation ulcers in
two patients following extravasation of 201Tl-thallous chloride
were the most severe injuries reported [43, 44]. In one case a
radiation ulcus was diagnosed 2 years. The injected activity and
estimated tissue dose were 74 MBq and 200 Gy, respectively
[43]. In the second case the diagnosis radiation ulcus was made
after 3 years. The injected activity was 111 MBq and the worst
case estimate of tissue dose was 250 Gy [44]. A pruritic and
erythematous patch was described following the extravasation
of 34 MBq of 131I-iodocholesterol, with a worst case tissue
dose estimate of 490 Gy [42]. Other reported cases of diagnos-
tic extravasation cases did not describe dosimetric parameters
or follow-up.
Eight publications reported a total of 10 cases of therapeu-
tic radiopharmaceutical extravasation [46–53]. Radionecrosis
was the most severe symptom reported in five cases [47, 49,
50], although three cases reported needle track necrosis
that resolved spontaneously [47]. The results and references
are summarised in Table 3. Table 4 summarises a total of 34
interventions that are advised or, contrarily, discouraged in
literature and those which are applied in reported cases.
Discussion
Multiple retrospective case series on bone scintigraphy, as well
as 18F-FDG positron emission tomography (PET) report a
large proportion of at least partial tracer extravasation
[18–31]. Although there was no clinical follow-up after extrav-
asation reported in these publications, no adverse reactions have
Table 2 Summary of reported cases of diagnostic radiopharmaceutical extravasation
References Total reported
cases
Radiopharmaceutical No. of patients
with reported
radiation injury
No. of patients
with reported
follow-up
Most severe
injury reported
[8–17] 332 18F-FDG 0 0
[18–31] 2584 99mTc bone tracers 0 0
[32] 3 99mTc-MAA 0 0
[33] 1 99mTc-DMSA 0 0
[34, 35] 10 99mTc-DTPA 0 0
[36] 1 99mTc-HMPAO 0 0
[37] 1 99mTc-MAG3 0 0
[19, 38, 39] 15 99mTc-pertechnetate 0 0
[40, 41] 2 99mTc-sestamibi 0 0
[19] 38 99mTc-sulfurcolloid 0 0
[19] 16 99mTc-microspheres 0 0
[42] 1 131I-iodocholesterol 1 1 Erythematous plaque
and pruritus.
[43–45] 12 201Tl-thallous chloride 2 2 Radiation ulcer
Total 3016 3 3
Eur J Nucl Med Mol Imaging
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been reported following extravasation of widely and frequently
used 99mTc labelled radiopharmaceuticals. Similarly, no cases
have been found with any symptoms after extravasation of
99mTc, 123I, 18F, and 68Ga labelled radiopharmaceuticals.
These radiopharmaceuticals together comprise a great majority
of radiopharmaceuticals in use on a daily basis in general nu-
clear medicine practices. Lack of clinical follow-up after diag-
nostic nuclear medicine scans, but also a conservative attitude
towards reporting and publishing of complications may have
possibly lead to under-reporting of skin lesions. Nevertheless,
given the long history of frequent usage of these agents and
even in case of significant under-reporting, we would have
expected that at least a few cases had been reported.
Therefore, we consider it safe to be conservative in treatment
of extravasation of these tracers. Attention should only be fo-
cused on early complications of the extravasation that are not
attributable to the radioactivity, such as skin necrosis and com-
partment syndrome [65, 66]. Other diagnostic radiopharmaceu-
ticals were reported to cause at least mild skin lesions, notably
201Th-thallous chloride and 131I-iodine-iodocholesterol. Only a
few publications report these cases, which are further elucidated
by only limited provided data on dosimetric data, follow-up of
the patients, etc. [42–44]. Particularly the long period of 2 and
3 years after 201Th-thallous chloride raise questions whether the
skin lesions were radiation induced. Furthermore, it should be
mentioned that 131I-iodine-iodocholesterol is used only sporad-
ically nowadays. Nevertheless, in our opinion this warrants at
least minimal preventive measures and follow-up after extrav-
asation of these tracers.
Few complications following therapeutic extravasation
were reported, yet some causing severe soft tissue damage.
Considering the high prevalence of extravasation in diagnostic
procedures, the same could be true for therapeutic radiophar-
maceuticals. Nevertheless, it is plausible that generally more
care is taken in preventing extravasation.
Therapeutic options
Applied and advised interventions are mostly derived from
treatment regimens of extravasation of non-radioactive agents.
Only few were applied in reported cases. Dispersive actions
can be effective in extravasation non-radiopharmaceutic agents
[65, 66]. It can be debated if all listed dispersive interventions
can be applied to radiopharmaceuticals. For instance, DeNardo
argues that hyperthermia can ameliorate success of radiothera-
py, similarly it might do more harm in case of extravasation
[59]. On the other hand, it is plausible that warming up the
tissue to promote hyperaemia and lymphatic flowmight reduce
the time of exposition enough to at least compensate this
radiosensitising effect. Terwinghe et al. showed fast tissue wash
out of 90Y-DOTATOC after arm elevation, warming the infil-
trated area and squeezing a stress ball. This patient had no soft
tissue symptoms during follow-up. Moreover they argue that
the relatively low molecular weight contributes to faster tissue
wash out, in comparison to radiopharmaceuticals with higher
molecular weight, particularly in case of 90Y-ibritumomab
tiuxetan [51]. Concentrating the radiopharmaceutical by
cooling the tissue can be applied in anticipation of surgical
interventions. Only two cases report the use of surgical tech-
niques. Local puncture was not considered successful after ex-
travasation of 90Y-dotatate [51]. In one report from 1950 the
ulceration was excised [49]. Other surgical treatments have not
been described or advised in literature. Pharmacotherapeutical
interventions have been reported in sporadic case reports.
Ulcers were treated with antibiotics and discomfort was treated
with topical steroids [46, 49, 50, 52, 53]. Intralesional cortico-
steroid therapy is advised by Williams, based on results after
chemotherapy extravasation, but has not been reported in ra-
diopharmaceutical extravasation [52]. Hyaluronidase use is
based on results in extravasation of other agents [1, 55], and
applied in one case report of 201Tl-thallous chloride extrava-
sation [45]. Williams et al. discourage any use, because of the
experimental status [52]. Amifostine might be effective in ra-
diopharmaceutical extravasation for its proven radioprotective
properties in radiotherapy [46]. Despite, it remains unknown
how it performs in the high linear energy transfer radiation
environment of radiopharmaceutical extravasation, while hav-
ing considerable side effects.
Clearance evaluation and dosimetry are often advised to be
part of extravasation management. Different methods have
been used, yielding a large range of tissue doses, due to un-
certainties such as retained activity and the volume of the
infiltrated tissue, as well as the use of worse case scenarios
[44, 46, 48, 49, 52, 53, 60, 61]. Sequential activity measure-
ments with probes or gamma-camera can give useful insight in
biological half-life, as well as effectiveness of applied inter-
ventions [42, 51, 52]. Furthermore, it might be helpful to also
estimate the amount, meaning the volume, of extravasation as
one can assume, that larger volumes of radioactive extravasa-
tion might cause more pronounced side effects than smaller
amounts. However, the volume of an extravasation is hardly
measurable, at least in the clinical setting and, consequently, to
define. This is not only because of the Breal time^ setting, but
it is even more difficult based on a retrospective literature
search and analyses. Furthermore, preventive measures are
reported, such as the use of an intravenous catheter (IV-
catheter) and adequate check of patency for both diagnostic
as well as therapeutic extravasation [1, 2, 4, 46, 50, 51, 55–57].
Limitations
A substantial number of publications reporting on extravasa-
tion, or which were otherwise relevant, were found by screen-
ing bibliographies and not in the initial search, despite the
sensitive elaborate search strategy. This can be at least partial-
ly explained by mismatches in searched keywords and the
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subject of the publication. For instance, a number of publica-
tions about pitfalls in image interpretation contained a brief
case report of extravasation as an example for false positive
lymph node visualisation. These publications were filtered out
in our initial search because they did not contain the right
keywords in title, abstract or keyword index. Similarly, some
patient studies investigating a particular tracer for evaluation
of a specific pathology also report extravasation, but were also
filtered out because no keywords relevant for our search were
matched. Others were brief case reports or Bimage of the
month^-type of publications without an abstract, but
contained some relevant information in image captions.
Finally, we found several congress abstracts for oral or poster
presentations that were not indexed in PubMed or Embase.
This is a minor shortcoming in our literature search, although
the publications that were found this way only reported min-
imal information on tracer extravasation. Moreover, it is chal-
lenging to avoid such difficulties.
We did not analyse the effect of extravasation on the image
quality of diagnostic nuclear medicine scans. It is obvious that
image quality might significantly be hampered by at least
large extravasation leading to a lower degree of tracer uptake
in the target tissue (organ) and to the potential need for a new
scan. However, as we, in this review, are focusing on clinical
consequences for the patients, we do not address this issue in
detail. Furthermore, because of the design of the study,
gaining more insights into this topic is not possible within
the context of this review.
Future perspectives
The lack of data on interventions underlines the need for fur-
ther scientific exploration on this subject. Future research is
required to establish definite conclusions for all used radio-
pharmaceuticals, by retrospective or preferably prospective
studies of extravasation cases with detailed clinical descrip-
tion, activity measurements, as well as serial scans to assess
dynamic behaviour of the tracer in the time after extravasation.
Furthermore, similar studies can be performed to evaluate the
different therapies possible after extravasation. Alternatively,
detailed case reports can proof to be helpful, especially for less
used and probably less common extravasation of therapeutic
radiopharmaceuticals. Nevertheless, trials performed in cen-
tres that treat large numbers of patients with nuclear medicine
therapies are preferable.
Local protocol
In our clinic, every injection of diagnostic and therapeutic
radiopharmaceutical is performed via an IV-catheter, preceded
Stop infusion and alert
nuclear physician.
Diagnostic/therapeutic
Radiopharmaceutical?
No
Extravasation of
radiopharmaceutical
observed.
Withdraw as much
radiopharmaceutical as
possible and leave IV catheter
in situ.Store syringe for
measurements.
When possible, delineate the
edges of the lesion.
Isotope other than 99mTc,
123I, 18F, 68Ga?
No
Is surgical intervention
required? (In case any one
of the symptoms in table 5 is
present)
Diagnostic
Consult plastic surgeon.
Consult radiological safety
officer for contamination
measures at OR (double
gloves, waste management).
Yes/Possibly
Apply warm compress for 20
min. at extravasation site,
repeat 3 times at 6, 18, and
24 hours. Inform patient to
keep injection site raised for
24h.
Yes
Remove IV catheter.
Continue scan if possible.
No
Inform patient.
Fill out registration form and
file complication.
Cool lesion with cold
compress to prevent local
spread.
Therapeutic
Apply warm compress for
20 min. at extravasation
site, repeat 3 times at 6,
18, and 24 hours. Inform
patient to keep injection
site raised for 24h.
Plan telephone follow up
after 1 month.
No therapy or follow up
required.
Consult plastic surgeon.
Is surgery opted?
No
Consult radiological safety
officer for contamination
measures at OR (double
gloves, waste management).
Yes
Make arrangements for
clinical follow up by plastic
surgeon.
Consult physicist to
determine method and
strategy for activity
measurements.
Fig. 1 Flowchart describing the protocol in use in Maastricht University Medical Center for management of radiopharmaceutical extravasation
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by a check of patency that includes flushing the IV-catheter
with saline solution, while visually inspecting if swelling oc-
curs and asking the patient if he experiences discomfort during
injection. Furthermore, some blood is drawn.When patency is
doubtful, a second IV-catheter is inserted and checked for
patency. Alternatively, in patients with difficult venous access,
this step can be preceded by injecting 99mTc-pertechnetate
with the patient’s thorax positioned under a gamma camera,
to visually confirm systemic spread. For therapeutic adminis-
trations, patency is always checked under supervision of the
nuclear physician.
Figure 1 shows the protocol that is in use in our hospital for
management of radiopharmaceutical extravasation. It is based
on the findings of this review. It reflects the negligible proba-
bility of adverse events in frequently used 99mTc, 123I, 18F and
68Ga labelled tracers by a conservative approach. A more care-
ful approach has been chosen with relatively harmless preven-
tive measures for diagnostic tracers combined with follow-up,
in case of tracers for which adverse events have been reported,
notably 201Tl-thallous chloride, and for tracers no literature of
extravasation was found at all. Although in general radiophar-
maceutical administration volume is limited, severe conse-
quences have been reported in non-radiopharmaceutical extrav-
asation, such as tissue necrosis and compartment syndrome [65,
66]. Therefore, in case of any of the symptoms listed in Table 5,
the plastic surgeon is consulted. For therapeutic extravasation a
plastic surgeon is always consulted to discuss the usefulness of
surgery. Until the decision for surgical intervention is made, the
lesion is cooled to spare surrounding tissue by preventing
spread of the radiopharmaceutical. If no surgical intervention
is opted, frequently warming the extravasation area and eleva-
tion of the arm are advised to promote spreading of the radio-
pharmaceutical. Repetitive gamma camera measurements are
performed in case of therapeutic extravasation in consultation
with the physicist. The patient should always be informed about
treatment and potential complications. All cases of extravasa-
tion in our hospital are being recorded using a standard form
containing detailed information, such as symptoms, the location
of extravasation, injected volume and activity, as well as treat-
ment. Furthermore, the incident is documented for the local
complication committee. The strategy applied in this protocol
ensures an efficient workflow, by minimizing the effort needed
for the most frequently used tracers.
Conclusions
Extravasation of diagnostic radiopharmaceuticals is common.
Often used 99mTc, 123I, 18F, and 68Ga labelled tracers do not
require specific intervention. Sporadic reports of extravasation
of other diagnostic radiopharmaceuticals, however, have de-
scribed soft tissue lesions. Dispersive intervention and follow-
up is, therefore, advised in other diagnostic radiopharmaceuti-
cals. Extravasation of therapeutic radiopharmaceuticals can
lead to severe soft tissue lesions. Although not evidence based,
surgical intervention should be considered. Furthermore, dis-
persive intervention, dosimetry and follow-up is advised.
Pharmaceutical intervention has no place yet in the immediate
care of radiopharmaceutical extravasation.
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